Abstract
Follow-up after transurethral resection of bladder tumor (TURBT) for non-muscle-invasive bladder cancer (NMIBC) is necessary because of the significant risk of recurrence and progression. Cystoscopy remains the standard method for follow-up. When the first follow-up cystoscopy at 3 months after TURBT is negative, the following cystoscopies are traditionally repeated every 3 months for a period of 2 years, then every 6 months until the end of the fifth year, and yearly thereafter. This approach can now be tailored depending on individual risk of recurrence and progression. Low-risk patients can be discharged from cystoscopic follow-up after being free of recurrence for 5 years. In patients with a history of high-risk NMIBC including carcinoma in situ, urinary cytology should be used as an adjunct to cystoscopy with lifelong bladder follow-up and yearly upper tract imaging. Currently, urine markers have no adequate evidence-based role in the follow-up of NMIBC. A follow-up regimen for intermediate-risk patients is less clearly definable. It should be between low- and high-risk regimens according to the current guidelines. In summary, surveillance strategies should be individualized based on the risk of cancer recurrence at the bladder and extravesical sites.
| Original language | English |
|---|---|
| Title of host publication | Bladder Cancer |
| Publisher | Elsevier Inc. |
| Pages | 541-551 |
| Number of pages | 11 |
| ISBN (Electronic) | 9780128099407 |
| ISBN (Print) | 9780128099391 |
| DOIs | |
| Publication status | Published - 2017 Dec 14 |
Fingerprint
Keywords
- Bladder
- Cancer
- Non-muscle
- Surveillance
ASJC Scopus subject areas
- Medicine(all)
Cite this
Surveillance for Non-Muscle-Invasive Bladder Cancer. / Shim, Ji Sung; Kang, Sung-Gu.
Bladder Cancer. Elsevier Inc., 2017. p. 541-551.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Surveillance for Non-Muscle-Invasive Bladder Cancer
AU - Shim, Ji Sung
AU - Kang, Sung-Gu
PY - 2017/12/14
Y1 - 2017/12/14
N2 - Follow-up after transurethral resection of bladder tumor (TURBT) for non-muscle-invasive bladder cancer (NMIBC) is necessary because of the significant risk of recurrence and progression. Cystoscopy remains the standard method for follow-up. When the first follow-up cystoscopy at 3 months after TURBT is negative, the following cystoscopies are traditionally repeated every 3 months for a period of 2 years, then every 6 months until the end of the fifth year, and yearly thereafter. This approach can now be tailored depending on individual risk of recurrence and progression. Low-risk patients can be discharged from cystoscopic follow-up after being free of recurrence for 5 years. In patients with a history of high-risk NMIBC including carcinoma in situ, urinary cytology should be used as an adjunct to cystoscopy with lifelong bladder follow-up and yearly upper tract imaging. Currently, urine markers have no adequate evidence-based role in the follow-up of NMIBC. A follow-up regimen for intermediate-risk patients is less clearly definable. It should be between low- and high-risk regimens according to the current guidelines. In summary, surveillance strategies should be individualized based on the risk of cancer recurrence at the bladder and extravesical sites.
AB - Follow-up after transurethral resection of bladder tumor (TURBT) for non-muscle-invasive bladder cancer (NMIBC) is necessary because of the significant risk of recurrence and progression. Cystoscopy remains the standard method for follow-up. When the first follow-up cystoscopy at 3 months after TURBT is negative, the following cystoscopies are traditionally repeated every 3 months for a period of 2 years, then every 6 months until the end of the fifth year, and yearly thereafter. This approach can now be tailored depending on individual risk of recurrence and progression. Low-risk patients can be discharged from cystoscopic follow-up after being free of recurrence for 5 years. In patients with a history of high-risk NMIBC including carcinoma in situ, urinary cytology should be used as an adjunct to cystoscopy with lifelong bladder follow-up and yearly upper tract imaging. Currently, urine markers have no adequate evidence-based role in the follow-up of NMIBC. A follow-up regimen for intermediate-risk patients is less clearly definable. It should be between low- and high-risk regimens according to the current guidelines. In summary, surveillance strategies should be individualized based on the risk of cancer recurrence at the bladder and extravesical sites.
KW - Bladder
KW - Cancer
KW - Non-muscle
KW - Surveillance
UR - http://www.scopus.com/inward/record.url?scp=85054769392&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054769392&partnerID=8YFLogxK
U2 - 10.1016/B978-0-12-809939-1.00029-1
DO - 10.1016/B978-0-12-809939-1.00029-1
M3 - Chapter
SN - 9780128099391
SP - 541
EP - 551
BT - Bladder Cancer
PB - Elsevier Inc.
ER -